copyright © 2011 research to practice. all rights reserved. faculty national gi tumor board...
TRANSCRIPT
![Page 1: Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current](https://reader035.vdocument.in/reader035/viewer/2022062517/56649f225503460f94c3b708/html5/thumbnails/1.jpg)
Copyright © 2011 Research To Practice. All rights reserved.
Faculty
National GI Tumor Board
Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer
Friday, January 21, 20117:00 PM – 9:30 PM
San Francisco, California
ModeratorNeil Love, MD
Eileen M O’Reilly, MDEric Van Cutsem, MD, PhD Andrew X Zhu, MD, PhD
Charles D Blanke, MDDavid Cunningham, MDSteven A Curley, MD
![Page 2: Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current](https://reader035.vdocument.in/reader035/viewer/2022062517/56649f225503460f94c3b708/html5/thumbnails/2.jpg)
Copyright © 2011 Research To Practice. All rights reserved.
Case presented by Dr Polkinghorn
• 66 yo man: PMH- Hepatitis C and rising AFP (120K)– ? missed diagnosis, now multiple hepatic lesions
consistent with HCC. Child Pugh B cirrhosis • 2/2010: Treated with TACE x 3 falling AFP• Sorafenib (before and following TACE) x 4-6 mos
– AFP to 300 but toxicity (? related to underlying cirrhosis)
• Cytopenias, HFS, diarrhea, abdominal pain• Sorafenib on hold. AFP remains low
![Page 3: Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current](https://reader035.vdocument.in/reader035/viewer/2022062517/56649f225503460f94c3b708/html5/thumbnails/3.jpg)
Copyright © 2011 Research To Practice. All rights reserved.
![Page 4: Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current](https://reader035.vdocument.in/reader035/viewer/2022062517/56649f225503460f94c3b708/html5/thumbnails/4.jpg)
Copyright © 2011 Research To Practice. All rights reserved.
Case presented by Dr Polkinghorn
• 66 yo man: PMH- Hepatitis C and rising AFP (120K)– ? missed diagnosis, now multiple hepatic lesions
consistent with HCC. Child Pugh B cirrhosis • 2/2010: Treated with TACE x 3 falling AFP• Sorafenib (before and following TACE) x 4-6 mos
– AFP to 300 but toxicity (? related to underlying cirrhosis)
• Cytopenias, HFS, diarrhea, abdominal pain• Sorafenib on hold. AFP remains low
![Page 5: Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current](https://reader035.vdocument.in/reader035/viewer/2022062517/56649f225503460f94c3b708/html5/thumbnails/5.jpg)
Copyright © 2011 Research To Practice. All rights reserved.
![Page 6: Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current](https://reader035.vdocument.in/reader035/viewer/2022062517/56649f225503460f94c3b708/html5/thumbnails/6.jpg)
Copyright © 2011 Research To Practice. All rights reserved.
Case presented by Dr Polkinghorn
• 66 yo man: PMH- Hepatitis C and rising AFP (120K)– ? missed diagnosis, now multiple hepatic lesions
consistent with HCC. Child Pugh B cirrhosis • 2/2010: Treated with TACE x 3 falling AFP• Sorafenib (before and following TACE) x 4-6 mos
– AFP to 300 but toxicity (? related to underlying cirrhosis)
• Cytopenias, HFS, diarrhea, abdominal pain• Sorafenib on hold. AFP remains low
![Page 7: Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current](https://reader035.vdocument.in/reader035/viewer/2022062517/56649f225503460f94c3b708/html5/thumbnails/7.jpg)
Copyright © 2011 Research To Practice. All rights reserved.
First Interim Results of the Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma (HCC) and of its Treatment with Sorafenib (GIDEON) Study: Use of Sorafenib by Oncologists and Nononcologists in the Management of HCC
Venook AP et al. Proc ASCO GI 2011;Abstract 157
![Page 8: Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current](https://reader035.vdocument.in/reader035/viewer/2022062517/56649f225503460f94c3b708/html5/thumbnails/8.jpg)
Copyright © 2011 Research To Practice. All rights reserved.
GIDEON Study: First Interim Analysis
Venook AP et al. Proc ASCO GI 2011;Abstract 157.
42%
76%
28%
35%
0% 20% 40% 60% 80% 100%
TreatmentEmergent
Serious AEs
Sorafenib 800 mgInitial Dose
CP-B
Stage 4
![Page 9: Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current](https://reader035.vdocument.in/reader035/viewer/2022062517/56649f225503460f94c3b708/html5/thumbnails/9.jpg)
Copyright © 2011 Research To Practice. All rights reserved.
Case presented by Dr Polkinghorn
• 66 yo man: PMH- Hepatitis C and rising AFP (120K)– ? missed diagnosis, now multiple hepatic lesions
consistent with HCC. Child Pugh B cirrhosis • 2/2010: Treated with TACE x 3 falling AFP• Sorafenib (before and following TACE) x 4-6 mos
– AFP to 300 but toxicity (? related to underlying cirrhosis)
• Cytopenias, HFS, diarrhea, abdominal pain• Sorafenib on hold. AFP remains low
![Page 10: Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current](https://reader035.vdocument.in/reader035/viewer/2022062517/56649f225503460f94c3b708/html5/thumbnails/10.jpg)
Copyright © 2011 Research To Practice. All rights reserved.
Faculty
National GI Tumor Board
Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer
Friday, January 21, 20117:00 PM – 9:30 PM
San Francisco, California
ModeratorNeil Love, MD
Eileen M O’Reilly, MDEric Van Cutsem, MD, PhD Andrew X Zhu, MD, PhD
Charles D Blanke, MDDavid Cunningham, MDSteven A Curley, MD
![Page 11: Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current](https://reader035.vdocument.in/reader035/viewer/2022062517/56649f225503460f94c3b708/html5/thumbnails/11.jpg)
Copyright © 2011 Research To Practice. All rights reserved.
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial
Abou-Alfa GK et al.JAMA 2010;304(19):62154-60
![Page 12: Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current](https://reader035.vdocument.in/reader035/viewer/2022062517/56649f225503460f94c3b708/html5/thumbnails/12.jpg)
Copyright © 2011 Research To Practice. All rights reserved.
Case presented by Dr Polkinghorn
• 66 yo man: PMH- Hepatitis C and rising AFP (120K)– ? missed diagnosis, now multiple hepatic lesions
consistent with HCC. Child Pugh B cirrhosis • 2/2010: Treated with TACE x 3 falling AFP• Sorafenib (before and following TACE) x 4-6 mos
– AFP to 300 but toxicity (? related to underlying cirrhosis)
• Cytopenias, HFS, diarrhea, abdominal pain• Sorafenib on hold. AFP remains low